Electrophysiological, neurochemical and regional effects of levetiracetam in the rat pilocarpine model of temporal lobe epilepsy

被引:60
作者
Klitgaard, H [1 ]
Matagne, A [1 ]
Grimee, R [1 ]
Vanneste-Goemaere, J [1 ]
Margineanu, DG [1 ]
机构
[1] UCB SA Pharma Sector, Res & Dev, Preclin CNS Res, B-1420 Braine lAlleud, Belgium
来源
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY | 2003年 / 12卷 / 02期
关键词
pilocarpine; levetiracetam; antiepileptic drugs; temporal lobe epilepsy; rat;
D O I
10.1016/S1059131102001930
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This study compared levetiracetam (Keppra(R)) with reference antiepileptic drugs (AEDs) in the rat pilocarpine model of temporal lobe epilepsy. Electroencephalogram (EEG) recordings showed that i.p. administration of valproate (300 nig/kg). phenobarbital (5 mg/kg) and clonazepam (0.5 mg/kg) all significantly delayed the appearance of the first epileptic spike discharge in hippocampus as well as synchronous epileptiform activity in hippocampus and cortex. In contrast, i.p. administration of levetiracetam (17 mg/kg) only significantly delayed the appearance of the latter. This was corroborated by findings showing that i.p. administration of levetiracetam (17 mg/kg) significantly opposed pilocarpine-induced increases, in the amplitude of the orthodromic population spike in the hippocampal CA3 area of urethane-anaesthetised rats, while valproate (200 mg/kg), phenobarbital (10 mg/kg) and clonazepam (1 mg/kg) had no effect, Pre-treatment i.p. with phenobarbital (10 mg/kg) and clonazepam (0.5 mg/kg) significantly reversed seizure-induced changes in aspartate and GABA concentrations while valproate (300 mg/kg) significantly reduced aspartate concentrations further. In contrast,. levetiracetam (34 mg/kg) significantly counteracted all seizure-induced alterations in amino acid concentrations, Midazolam induced significant seizure protection after microinjection into substantia nigra pars reticulata (SNR. 50 nmol), nucleus accumbens (NA. 25 nmol) and caudate putamen (CP 25 nmol), whereas phenytoin (50 nmol) only showed significant seizure protection after injection into the latter area. Levetiracetam differed by significant seizure protection after injection into SNR ( 1000 nmol and NA 0000 nmol. These results suggest that le levetiracetam is distinct from other AEDs by its ability to selectively suppress synchronisation of neuronal spike and burst firing in hippocampus. (C) 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 25 条
[1]  
Andersen P, 1975, HIPPOCAMPUS, P155, DOI DOI 10.1007/978-1-4684-2976-3_7
[2]   Levetiracetam (ucb L059) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission [J].
Birnstiel, S ;
Wulfert, E ;
Beck, SG .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 356 (05) :611-618
[3]   SPONTANEOUS RECURRENT SEIZURES IN RATS - AMINO-ACID AND MONOAMINE DETERMINATION IN THE HIPPOCAMPUS [J].
CAVALHEIRO, EA ;
FERNANDES, MJ ;
TURSKI, L ;
NAFFAHMAZZACORATTI, MG .
EPILEPSIA, 1994, 35 (01) :1-11
[4]  
FRAZER CM, 1997, EPILEPSIA S3, V38, P177
[5]   Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy [J].
Klitgaard, H ;
Matagne, A ;
Gobert, J ;
Wülfert, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) :191-206
[6]   The novel antiepileptic drug levetiracetam (ucb L059) induces alterations in GABA metabolism and turnover in discrete areas of rat brain and reduces neuronal activity in substantia nigra pars reticulata [J].
Loscher, W ;
Honack, D ;
BlomsFunke, P .
BRAIN RESEARCH, 1996, 735 (02) :208-216
[7]  
MADEJA M, 2001, EPILEPSIA S2, V42, P19
[8]  
Margineanu DG, 2000, PHARMACOL RES, V42, P281
[9]   UCB L059, A NOVEL ANTICONVULSANT, REDUCES BICUCULLINE-INDUCED HYPEREXCITABILITY IN RAT HIPPOCAMPAL CA3 IN-VIVO [J].
MARGINEANU, DG ;
WULFERT, E .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 286 (03) :321-325
[10]   Inhibition by levetiracetam of a non-GABA(A) receptor-associated epileptiform effect of bicuculline in rat hippocampus [J].
Margineanu, DG ;
Wulfert, E .
BRITISH JOURNAL OF PHARMACOLOGY, 1997, 122 (06) :1146-1150